• The Eli Lilly of inhaled insulin.
• The Dyson of inhaled drug delivery.
• Like a specialized Vertex Pharmaceuticals, but focused on inhaled treatments for endocrine and orphan lung diseases.

• Afrezza: An inhaled insulin used to improve glycemic control in adults with diabetes.
• Thyquidity: A product promoted for the treatment of hypothyroidism.
• ZYESAMI (aviptadil): A dry powder formulation under development in collaboration with NRx Pharmaceuticals to help protect cells against inflammatory conditions.

MannKind Corporation (MNKD) sells its products primarily to other companies within the healthcare supply chain and through strategic collaborations. Its major customers include:

• Pharmaceutical Wholesalers: These companies are the primary direct purchasers of MannKind’s commercial products, such as Afrezza and Thyquidity, for distribution to pharmacies, hospitals, and other healthcare providers. The largest pharmaceutical wholesalers in the United States, which typically serve as major customers for biopharmaceutical companies, include:
  • McKesson Corporation (MCK)
  • Cardinal Health, Inc. (CAH)
  • AmerisourceBergen Corporation (ABC)
• United Therapeutics Corporation (UTHR): As per the company description, MannKind has a license and collaboration agreement with United Therapeutics Corporation. This agreement indicates that United Therapeutics is a significant partner and customer for licensed products or services related to their collaboration.
• NRx Pharmaceuticals (NRXP): MannKind has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI. This type of development agreement often involves payments for services or future product supply, making NRx Pharmaceuticals a customer in this context.

• United Therapeutics Corporation (UTHR)
• Bachem AG (BANB)
• Dr. Reddy's Laboratories Ltd. (RDY)

Michael Castagna, Chief Executive Officer

Michael Castagna became CEO of MannKind Corporation and joined its board of directors in 2017, bringing over 25 years of experience in healthcare, pharmaceuticals, and biotechnology to the company's product and medical device development strategy. Prior to MannKind, he served as Vice President at Amgen, where he guided both the Lifecycle Management and Global Commercial Biosimilar business areas. He spent a combined 10 years at Bristol-Myers Squibb, focusing on medical, marketing, and sales, and also directed their Immunoscience division. His other industry experience includes serving as a Vice President at Sandoz (Novartis), where he established the U.S. Biologics Business Unit, and as a Director at Merck, Serono, Pharmasset, and DuPont Pharmaceuticals.

Christopher Prentiss, Chief Financial Officer

Christopher Prentiss was appointed Chief Financial Officer of MannKind Corporation effective April 22, 2024. He brings over two decades of financial leadership experience within the biopharma sector. Prior to joining MannKind, Mr. Prentiss served as CFO of ADARx Pharmaceuticals, where he helped facilitate a funding round of nearly $250 million. His professional history also includes a tenure as CFO at Adamas Pharmaceuticals, where he contributed to significant company milestones such as product launches and revenue growth.

Dominic Marasco, President, Endocrine Business Unit

Dominic Marasco joined MannKind Corporation as President, Endocrine Business Unit, effective January 6, 2025. He has over 25 years of experience in driving commercial success within the biopharma and biotech sectors. Mr. Marasco previously held the position of Executive President, Chief Commercial Officer for Envision Pharma Group, and prior to that, he was Chief Commercial Officer at BioAgilytix Labs, Inc. His background also includes leadership roles at Syneos Health, Amgen, and Sandoz Biopharmaceuticals.

Ajay Ahuja, Executive Vice President and Chief Medical Officer

Dr. Ajay Ahuja joined MannKind Corporation as Executive Vice President and Chief Medical Officer in 2025, with his appointment effective September 29, 2025. A pediatrician and cardiologist, Dr. Ahuja is a seasoned biopharmaceutical leader with over two decades of industry experience. His expertise spans medical devices, drug delivery platforms, and biopharmaceuticals, particularly in therapeutic areas such as diabetes, cardiovascular disease, respiratory medicine, and infectious diseases. Before MannKind, Dr. Ahuja held leadership roles in clinical development, medical affairs, and commercial strategy at companies including Kardigan Bio, Takeda, Pfizer, GSK, and Novartis.

Sanjay Singh, Executive Vice President, Technical Operations

Sanjay Singh is MannKind's Executive Vice President of Technical Operations, leading the company's Danbury facility and overseeing commercial and contract manufacturing. He brings over 30 years of experience in pharmaceutical technical operations, having worked with multiple technologies, delivery systems, and therapeutic areas. Prior to joining MannKind in 2022, Mr. Singh was Associate President of Operations for Aurobindo Pharma USA and served as Senior VP of Operations for Aurobindo Pharma India.

The key risks to MannKind Corporation (MNKD) include the following, listed in order from most significant to least significant:

1. Dependence on United Therapeutics and Competition from New Products: MannKind is heavily reliant on its collaboration with United Therapeutics, particularly for royalties derived from Tyvaso DPI. A significant and immediate risk is United Therapeutics' recent unveiling of Tresmi, a soft-mist treprostinil inhaler, which has been described as a "category killer product" and could potentially compete with or replace Tyvaso DPI. This development introduces uncertainty regarding the long-term durability of MannKind's Tyvaso DPI royalties, a key revenue stream.
2. Regulatory and Market Adoption Challenges for Products: As a biopharmaceutical company, MannKind faces ongoing regulatory risks. Immediate risks include upcoming FDA decisions on the Afrezza pediatric sBLA in May 2026 and the Furoscix ReadyFlow Autoinjector sNDA in July 2026. Delays or negative outcomes in these regulatory processes could materially impact near-term growth expectations. Historically, Afrezza has also encountered significant market adoption hurdles, including issues with insurance coverage and the requirement for lung function tests, which could recur with new product introductions or expanded indications.
3. Need for Additional Capital and Financial Health: MannKind has a history of requiring additional capital to fund its operations, research and development activities, and commercialization efforts. Despite recent initiatives like a sale-leaseback transaction to generate capital, indicators such as a low Altman Z-Score suggest an elevated financial distress risk and highlight that interest payments are not consistently well covered by earnings. The company must continuously manage its financial health and access to capital to support its growth strategy and ongoing operations.

MannKind (MNKD) is expected to drive future revenue growth over the next 2-3 years through several key areas:

1. Continued Growth in Tyvaso DPI Royalties and Collaboration Revenue: MannKind's collaboration with United Therapeutics for Tyvaso DPI, an inhaled therapy for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, continues to be a significant revenue driver. The company receives royalties on net sales of Tyvaso DPI and revenue from its manufacturing activities. Strong patient demand for this product has consistently driven increased revenue, with MannKind anticipating receiving between $700 million and $1 billion in cash from Tyvaso over the next few years.
2. Expansion and Demand for Afrezza: Afrezza, MannKind's inhaled insulin product, is expected to see continued revenue growth driven by increasing patient demand, favorable pricing strategies, and improved gross-to-net adjustments. A significant anticipated catalyst is the potential FDA approval for a pediatric indication, with a decision expected by May 29th, 2026. Additionally, an FDA label update to simplify switching from injected insulin is expected to further support its adoption. International expansion efforts are also contributing to Afrezza's growth.
3. Growth of FUROSCIX with Autoinjector Launch: Following the acquisition of scPharmaceuticals, FUROSCIX has become a key growth engine within MannKind's cardiometabolic franchise. The anticipated approval of the FUROSCIX ReadyFlow Autoinjector, with a PDUFA date of July 26th, 2026, is considered a major catalyst. This autoinjector is expected to significantly expand market reach, particularly within hospitals, and accelerate sales growth, with MannKind aiming for FUROSCIX revenues in the range of $110 million to $120 million in 2026.
4. Advancement of Orphan Lung Disease Pipeline (MNKD-101 and MNKD-201): MannKind is actively advancing its pipeline products for orphan lung diseases. MNKD-101 (clofazimine inhalation suspension for NTM lung disease) is progressing into a global Phase 3 clinical trial. Furthermore, MNKD-201 (nintedanib DPI for Idiopathic Pulmonary Fibrosis - IPF) has successfully completed Phase 1 studies and is on track for further clinical development, including Phase 2/3 trials. Successful development and potential commercialization of these pipeline assets represent future revenue opportunities.

Share Issuance

• MannKind reached agreements in December 2024 to exchange approximately $193.7 million of its convertible senior notes for 26,749,559 shares of common stock and about $89.2 million in cash.
• The number of shares issued and outstanding increased from 302,959,782 as of December 31, 2024, to 307,832,587 as of December 31, 2025.
• Shares outstanding (diluted average) grew by 10.39% to $313.3 million in 2025 from $283.8 million in 2024, and by 6.3% in 2024 from $267.0 million in 2023.

Inbound Investments

• MannKind receives royalties from United Therapeutics for the sales of Tyvaso DPI, leveraging MannKind's Technosphere drug delivery technology.
• The company anticipates receiving $700 million to $1 billion in cash from Tyvaso over the next few years.
• A minimum supply agreement with United Therapeutics is expected to provide approximately $100 million in revenue for 2025 and 2026, and about $50 million annually thereafter, ensuring a predictable cash flow.

Outbound Investments

• MannKind successfully completed the acquisition of scPharmaceuticals Inc. in October 2025.
• This acquisition is projected to diversify and accelerate MannKind's double-digit revenue growth, primarily driven by FUROSCIX.

Capital Expenditures

• Capital expenditures for MannKind were $4.57 million in 2025, $9.69 million in 2024, and $42 million in 2023.
• In Q4 2025, capital expenditures amounted to $2.0 million.
• Capital expenditures absorb a significant portion of operating cash flow, contributing to a low free cash flow margin of 3.9%.